Traders Purchase Large Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was the target of some unusual options trading on Wednesday. Stock investors acquired 6,110 call options on the company. This represents an increase of approximately 44% compared to the average volume of 4,234 call options.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock traded up $5.32 during trading on Wednesday, hitting $22.93. 12,270,332 shares of the company’s stock traded hands, compared to its average volume of 2,842,179. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48. The stock has a market capitalization of $2.41 billion, a P/E ratio of -2.71, a PEG ratio of 0.28 and a beta of 0.42. The business has a 50-day simple moving average of $18.68 and a 200-day simple moving average of $19.94. Sarepta Therapeutics has a 1 year low of $10.41 and a 1 year high of $74.40.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The company had revenue of $442.93 million for the quarter, compared to analysts’ expectations of $390.95 million. During the same quarter last year, the company earned $1.90 earnings per share. The company’s revenue for the quarter was down 32.7% on a year-over-year basis. As a group, analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on SRPT shares. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Mizuho boosted their price target on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Wells Fargo & Company dropped their price objective on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Finally, Wedbush reduced their price objective on Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $32.15.

Sarepta Therapeutics News Roundup

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: First clinical siRNA data: Phase 1/2 results showed dose‑dependent muscle exposure, early biomarker effects and no dose‑limiting toxicity for SRP‑1001 and SRP‑1003 — the core reason shares jumped. Sarepta Announces First Clinical Data from siRNA Pipeline (BusinessWire)
• Positive Sentiment: Targeted delivery platform validated: company highlighted its αvβ6 integrin‑targeted delivery achieving high muscle concentrations — a technical milestone that increases the programs’ therapeutic plausibility. Proactive Investors coverage
• Positive Sentiment: Options and volume spike: unusually large call buying (about 6,110 calls, ~44% above typical daily call volume) and multi‑million share volume indicate speculative positioning and short‑term momentum traders piling in.
• Neutral Sentiment: Company webcast/presentation: management hosted a webcast to present the data, which increases transparency but leaves questions about longer‑term efficacy and pivotal plans. Yahoo Finance coverage of webcast
• Neutral Sentiment: Broader market tone: lower volatility and risk‑on flows today likely amplified biotech rallies, helping the headline reaction to Sarepta’s news. Market VIX note
• Negative Sentiment: Valuation and analyst caution: some analysts remain split — bullish on the siRNA potential but cautious on near‑term valuation and execution given Sarepta’s recent earnings volatility and prior EPS misses. Benzinga analysis
• Negative Sentiment: Clinical, regulatory and commercial risks remain: Phase 1/2 is early stage — durability, meaningful clinical benefit, dose optimization, safety in larger cohorts and regulatory path/timing are unresolved; the company also reported a prior big EPS miss and negative margins.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director directly owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. The trade was a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new position in Sarepta Therapeutics in the fourth quarter valued at $25,000. iSAM Funds UK Ltd purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at about $25,000. Ancora Advisors LLC raised its holdings in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares during the period. Byrne Asset Management LLC purchased a new position in Sarepta Therapeutics during the third quarter worth approximately $33,000. Finally, Allworth Financial LP grew its holdings in Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.